Loading
IX Biopharma Ltd. Stock: price and insider trades · Singapore
1 insider bought €1.0M of shares over the last 90 days, the latest by Oversea-Chinese Banking Corporation Limited, filed 26 Jul 2026.
IX Biopharma Ltd.: what insiders have been doing
IX Biopharma Ltd., classified in the Health Care sector, is a listed company. Its insiders report their share dealings to SGX. Over the twelve months to 22 October 2026, 17 filings were filed, from 11 insiders.
The record shows 9 purchases on the open market worth €2.3M, made by 8 insiders, against 3 sales worth €2.7M by 2 insiders. The amount is not disclosed for 1 filing. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 6 chief executives and 2 major shareholders among the declarants. At €1.7M, the sale published on 15 April 2026 by Eddy Lee Yip Hang is the largest of the period.
The data flag 5 purchases as part of a group of insiders buying within 30 days of each other. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. The last purchase on record was published on 26 July 2026, which is 89 days ago. The median gap between a trade and its publication by SGX is 2 days. The shorter that gap, the sooner other investors can see what insiders have done.
Across the 394 companies tracked on its exchange, the median is 6 filings; at 17 filings, this issuer sits above that mark. The full history, which starts in 2017, counts 29 purchases against 7 sales.
Every figure here comes from the filings published by SGX and describes the past, not future prices; it is not investment advice.
Insider Decl.
60
Thresholds
n/a
Buy Volume
€5M
29 ops. · all time
Sell Volume
€4M
7 ops. · all time
Who traded when
BuySaleEddy Lee Yip Hang3 buys1 sale
Albert Ho Shing Tung3 buys
Anson Properties Pte. Ltd.1 buy2 sales
Patrick Donald Davies2 buys
Teo Woon Keng John2 buys
Oversea-Chinese Banking Corporation Limited1 buy
Analyst consensus: bullish or bearish?
Analysts rate IX Biopharma Ltd. Strong Buy (bullish), based on 2 analysts. Average price target: SGD 1.09.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,505 of 26,289 companies
29.1
score / 100
Value29
Quality29
FCF yld-1.5%
Earn yld-1.5%
EV/EBITDA·
ROE-101%
Gross mgn36%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2026FY ended June 2026 · cache
SGD 0.48
Analyst consensus
2 analystsStrong buy
SGD 1.00Target SGD 1.09(+128%)SGD 1.17
Income statement
RevenueSGD 6.9M
Gross profitSGD 2.4M36% margin
EBITDA-SGD 6.6M-96% margin
Net income-SGD 8M-116.6% margin
Valuation
PER (trailing)0.8x
PER (forward)250.0x
P/Book33.9x
Beta1.01
Balance sheet & cash
Market capSGD 520.6M
Total debtSGD 5.8M
Free Cash Flow-SGD 7.6M
Debt / Equity38%
Profitability & ownership
ROE-101.4%
ROA-32.2%
% insiders36.5%
% institutions7.3%
Last declaration on 10 September 2026
Declarations60 total
1,000,000 shares@ SGD 0.5350.093% mcap20.4% of flowShareSGX-STISIN SG1BD9000009SGX:WADB6SKD1ROQ7106
3,712,800 shares@ SGD 0.40980.24% mcap100.0% of flowShareSGX-STISIN SG1BD9000009SGX:GR3S1SFYK5LDUZ0A
Canonical exit: 24 Oct 2026 (T+90)
11,620,807 shares@ SGD 0.060.11% mcap100.0% of flowShareSGX-STISIN SG1BD9000009SGX:L208TN0KOAROEIB8
Canonical exit: 13 Oct 2026 (T+90)
1,019,337 shares@ SGD 0.060.0095% mcap100.0% of flowShareSGX-STISIN SG1BD9000009SGX:4IQR9BITQ068YP58
Canonical exit: 12 Oct 2026 (T+90)
2,400,000 shares@ SGD 0.34445.7% of flowShareSGX-STISIN SG1BD9000009SGX:BEJ8HJISNQ6SNAT6
1,045,164 shares@ SGD 0.421524.3% of flowShareSGX-STSGX:SLN80GETDGQCU8Y2
Canonical exit: 11 Aug 2026 (T+90)
99,051 shares@ SGD 0.421566.0% of flowShareSGX-STSGX:AVU5UE8D1FXP9UQ7
Canonical exit: 11 Aug 2026 (T+90)
106,168 shares@ SGD 0.421566.3% of flowShareSGX-STSGX:YAES7Z9RUGM2MZ18
Canonical exit: 11 Aug 2026 (T+90)
99,051 shares@ SGD 0.421514.2% of flowShareSGX-STSGX:40Y2SM0H6NZAUBD4
Canonical exit: 11 Aug 2026 (T+90)
1,012,332 sharesShareSGX-STSGX:7DFZP3YZDQGXW2NQ
Canonical exit: 11 Aug 2026 (T+90)
3,036,996 sharesShareSGX-STISIN SG1BD9000009SGX:6P81CXTWRU4ZIVR3
10,000,000 shares@ SGD 0.2635.3% of flowShareSGX-STISIN SG1BD9000009SGX:IX6BUPG742FFIGAM
ShareSGX-STISIN SG1BD9000009SGX:RH06MYSV51E9AW8N
10,000,000 shares@ SGD 0.068.2% of flowShareSGX-STISIN SG1BD9000009SGX:WHML8UWPE374N2EZ
Canonical exit: 7 Jul 2026 (T+90)
ShareSGX-STISIN SG1BD9000009SGX:AZAG5QDQ7Y25ZAD3
ShareSGX-STISIN SGXN57296778SGX:PF6B6YTA0QG33IAQ
ShareSGX-STISIN SGXN57296778SGX:QCK2TWNG0MI98UMV
4,768,800 sharesShareSGX-STISIN SG1BD9000009SGX:JQ4WX0Y34N7A72SN
1,004,454 shares@ SGD 0.02233.7% of flowShareSGX-STISIN SG1BD9000009SGX:BPM2O9J5XJAC76F4
Canonical exit: 19 Jun 2025 (T+90)
948,863 shares@ SGD 0.02234.0% of flowShareSGX-STISIN SG1BD9000009SGX:RVU4NUULDUWV3QZ1
Canonical exit: 19 Jun 2025 (T+90)
961,454 shares@ SGD 0.0227.4% of flowShareSGX-STISIN SG1BD9000009SGX:VV46827KCDHE7OLD
Canonical exit: 19 Jun 2025 (T+90)
0ShareSGX-STISIN SGXN57296778SGX:F7GWELHTJWKQJMVG
2,038,675 shares@ SGD 0.0321.1% of flowShareSGX-STISIN SG1BD9000009SGX:RGJQ8F1HRUXDFXDL
Canonical exit: 17 Oct 2024 (T+90)
43,241,616 shares@ SGD 0.0317.9% of flowShareSGX-STISIN SGXN57296778SGX:BFF51013S2HMCGMP
Canonical exit: 17 Oct 2024 (T+90)
2,038,675 sharesShareSGX-STISIN SGXN57296778SGX:MYMHE1A47F90QE7M
25 of 60 declarations
About IX Biopharma Ltd.
IX Biopharma Ltd. is a company focused on developing pharmaceutical treatments, emphasizing research and innovation in the biopharmaceutical field.
